Column A	Column Header PIMMS Tracking ID (PIMMS USE ONLY)	Required/Optional? N/A	Instructions/Notes This is a unique ID that is used for PIMMS tracking purposes and internal use only.
B	(PIMMS USE ONLY) Input Row Completeness	N/A	
			Provides the status of "Complete" or "Incomplete" for each row. "Incomplete" will display if all of the REQUIRED fields have not bee populated for a given entry.
<u>c</u>	Error Messages for Required Fields	N/A	Provides the user with an error message(s) regarding missing REQUIRED information for each entry, Also. missing REQUIRED information for each entry will have the cell highlighted in red after five REQUIRED fields have been populated in the template for the specific proposed measure.
D	Measure Submission Status	Required	Indicate if the given entry is "Ready for PIMMS Team Review", a "Work in Progress" or "Withdrawn". Entries with a "Work in Progre status will not be reviewed until the status is updated to "Ready for PIMMS Team Review".
E	Do you own this measure?	Required	Tater "for," "No" or "G-owned" for this field. By selecting No", are attesting that you currently have the appropriate documental (i.e., email, letter) giving your organization permission from the Q- measure owner/showed to use the QOB measure. Documental measure owner/showed to use the QOB measure. Documental of the permission of the permission of the second "I your answer is no, you do not own the measure, please fill out columns E.P.G. and H. For remaining columns, please enter "see porter spect".
E	If you do not own or co-own this measure with another QCDR(s), please indicate the owner or co-owners	Optional	Provide the name of the QCDR that owns this measure or the QCDR(s) that co-own this measure. Example: Centers for Medicare & Medicaid Services
<u>6</u>	If this is a previously CMS approved measure, please provide the CMS assigned measure ID	Required	Provide the QCDR measure ID assigned to the 2017/2018/2019 M performance period approved measure included in the QCDR measure specifications. Enter "N/A" if not applicable. Example: ABC55
H	Measure Title	Required	Provide the measure title, which should begin with a clinical condi of focus, followed by a brief description of action. Example: Preventive Care and Screening: Screening for Depression and Follow-Up Plan.
1	Measure Description	Required	Describe the measure in full detail. Example: Percentage of patients aged 12 years and older screeners for depression on the date of the encounter using an age appropri- standardized deplacion screening tool AND I' positive, a follow-up alm is documented on the date of the positive screen.
1	Denominator	Required	Describe the eligible patient population to be counted to meet the measures' inclusion requirements. Example: All patients aged 12 years and older at the beginning of measurement period with at least one eligible encounter during th measurement period.
R	Numerator	Required	The clinical action that meets the requirements of the measure. Example: Patients screened for depression on the date of the encounter using an age appropriate standardized tool AND, if positive, a follow-up plan is documented on the date of the positiv screen.
L	Denominator Exclusions	Required	An exclusion is anything that would remove the patient, procedur or unit of measurement from the denominator. Enter "N/A" if not applicable. Example: Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of right and a left unilateral mastectomy.
M	Denominator Exceptions	Required	Allow for the exercise of clinical judgement. Applied after the numerator calculation and only if the numerator conditions are ni met. Inter "NA" in not applicable. Medical Rescoid-Schelten ki na urgent or emergent situation where time is of the essence and to delay treatment would be not applied to the statistical schedule and the schedule head of the schedule schedule and and the the patient's head that and Situations where the patient's functional capacity or motivation the provide schedule and schedule of standardized provides the patient's functional capacity or motivation the schedule schedule and the schedule of standardized transversion in provides the schedule of schedule and schedule and schedule and schedule and schedule transversion and schedule and the schedule of schedule transversion and schedule and the schedule and schedule transversion and schedule and the schedule transversion and schedule transversion and schedule and the schedule
N	Numerator Exclusions	Required	An exclusion is anything that would remove the patient, procedure or unit of measurement from the numerator, typically used in rat raciuston. Enter "N/A" if not applicable. Example: If the number of central fine blood stream infections per 1,000 catheter days were to exclude infections with a specific acterium, that bacterium would be listed as a numerator exclusion acterium, that bacterium would be listed as a numerator exclusion.
<u>0</u>	Data Source Used for the Measure	Required	Indicate the data source(s) used for the measure. This may includ but is not limited to administrative claims data, facility discharge data, chronic condition data warchouse (CCW), claims, CROWWW ENR (Inter relevant parts), Hyndi, IRF-2AL, LTOL CARE data set, record, Prescription Drug Event Data Elements, PROMS, record, record, Prescription Drug Event Data Elements, PROMS, record review, Registry (enter which Registry), Survey, Other (describe source).
P	If applicable, please enter additional information regarding the data source used	Optional	Provide additional information when "Registry" and/or "Other" is selected. Example: ABC Registry
Q	QCDR Measure Type	Required	Select the measure type from the drop down list that describes th measure submitted for review.
R	If this is an existing measure with changes, do the changes impact the intent of the measure?	Optional	Inclusion submittee on review. If yes, indicate if the variance is within your registry and/or from another source. If another source, please cite the source.
ŝ	Please indicate what has changed to the existing measure and how the change impacts the intent of the previous version.	Optional	Provide details regarding the measure changes and how the chan impact the previous version of the QCDR measure. Example: 10% improvement in depression symptoms has been ad to the numerator. The measure can no longer be benchmarked against the previous year.
I	Can the measure be benchmarked against the previous performance period data?	Optional	Enter "Yes" or "No" for this field.
Ŭ	If applicable, please Indicate why the previous benchmark cannot be used.	Optional	Provide details regarding why the previous benchmark cannot be used. Example: The improvement addition to the numerator will make to neasure an Outcome measure and therefore cannot be compared the measure from last year.
У	NQF ID Number (if applicable)	Optional	Provide the assigned NOF ID number, if the submitted QCDR meas fully aligns the NOF endorsed version of the measure. If no NOF IE number, enter 0000. Example: 0418
W	Is the QCDR measure a high priority measure?	Required	Enter "Yes" or "No" to indicate if the measure is a high priority measure.
X	High Priority Type	Required	Indicate the high priority measure type.
<u>¥</u> <u>Z</u>	Measure Type NQS Domain	Required Required	Select which measure type applies to the measure belongs. Select which NQS domain applies to the measure.
AA	Care Setting	Required	Select which care setting(s) are included within the measure.
<u>AB</u> AC	What Meaningful Measure Area applies to this measure? Meaningful Measure Area Rationale	Required	Select ONLY one Meaningful Measure Area that best applies to the measure. Provide a rationale for the selected Meaningful Measure Area for QCDR measure. Example: This measure identifies patients with depression and an appropriate follow-up treatment plan.

Please follow these steps when completing the QCDR measure submission template:
 1. Open the QCDR measure submission template and swel t with your organization's name (E. 2020 QCDR Measure Submission, CCDRName, vX). Please update the version number, when an updated QCR measure submission template and the probability of the probability of QCDR information. Tab. For estinging QCDR in good standing, please update row 3 GRH Avoimation ticket #1 and row 4 Number of QCDR Measure Submitted -1, For new QCDR, enter Information to all the row security for row 2 IQCR Method P1 applicable). The organization ticket #2 and row 4 Number of QCDR Measure Submitted -1, For new QCDR, enter Information to all the row security for row 2 IQCR Method P1 applicable). The organization template and QCDR Vietaries and the complete and required field denoted with an asterial (1). The table below shows and explosing of the probability of the row 1 QCR Measure Submitted or optical.
 4 Natigate to the '2020 QCR measure submission template to your capanization's 2020 self-nomination form. Please need the 2020 QCR measure submission template does not need to the 2020 and resonantion form to your applicable). 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to be not accel with a state state of the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does not need to the 2020 qcR measure submission template does nothe does and qcR qcR qcR apcR apcR applate does not need to the 2

The QCDR measure submission template should ONLY be filled out by QCDRs who meet the 2020 definition of a QCDR and wish to submit QCDR measures for CMS consideration. A QCDR may submit a maximum of 30 QCDR measures for review and approval by CMS for reporting. Complete the fields for each proposed 2020 MIPS Performance Period QCDR Measure. Please ensure that the measure description and specifications are checked for grammar and typographical errors before submission.

or populating the 2020 MIPS Pe

AD			
	Inverse Measure	Required	Indicate if the measure is on inverse measure. This is measure where lower calculated performance rate for this type of measure would indicate better clinical area or control. The "Performance Net Met" numerator option for an inverse measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases.
ΔE	Proportional Measure	Required	indicate if the measure is a proportional measure. This is a measure where the score is derived by dividing the number of cases that meet within a given time that the state of the state of the state of the within a given time trane (the dominiator). The numerator cases are a subset of the denominator cases (e.g., percentage of eligible women with a mammogram performed in the last year).
AE	Continuous Variable Measure	Required	Indicate if the measure is a continuous variable measure. This is a measure where a measure score in which each individual value for the measure can fail anywhere along a continuous acta and can be aggregated using a variety of methods such as the calculation of a mean or median (e.g., mean time to thrombolytics, which aggregates the time in minutes from a case presenting with chest pain to the time of administration of thrombolytics).
			CMS generating QCEBs to construct the numerators to be proportional by establishing an expected benchmark based on guidelines or national performance data, Applying MIPS scoring methodology has proven to be challinging for non-spontrolal measures because variability in the data points makes decile creation based on a mathematical analysis very unpredictable.
AG	Ratio Measure	Required	Indicate If the measure is a ratio measure. This is a measure where a score that may have a value of zero or greater that is derived by hilding a count of one type of data by a count of another type of data. The key to the definition of a ratio is that the numerator is not in the denominator (e.g., the number of patients with central lines who develop interion divided by the number of central line days). Rates closer to 1 represent the expected outcome.
AH	If Continuous Variable and/or Ratio is chosen, what is the range of the score(s)?	Optional	if not a continuous variable and/or ratio measure enter N/A. Example: 0-100%
А	Number of performance rates to be calculated and submitted	Required	Indicate the number of performance rates submitted for the measure. If only one is calculated, enter '1'.
<u>A</u>	Performance Bate Description(s)	Optional	Provide a brief description for each performance rate to be calculated was taken the performance rate in the calculated with 7 performance rates. I loweral Percentage for patient calculated with 7 performance rates. I loweral Percentage for patient calculated set of the well- controlled athma without elevated in 6 of excertainty with well- controlled athma, without elevated in 6 of excertainty with well- controlled athma, without elevated in 6 of excertainty with well- (athma) and a patients (aged 5-17 years) with well- (athma) and a patients (aged 15-50 years) with well- (athma) and a patients (aged 15-50 years) with well- controlled on the second
АК	Indicate an Overall Performance Rate if more than 1 performance rate is	Required	Specify which of the submitted rates will represent an overall performance rate for the measure or how an overall performance rate could be calculated based on the data submitted [for example,
	submitted		simple average of the performance rates submitted for example, simple average of the performance rates submitted or weighted average (sum of the numerators divided by the sum of the denominators), etc.
AL	Risk-Adjusted	Required	Indicate if the measure is risk-adjusted.
AM	If risk-adjusted, indicate which score is risk-adjusted	Required	Indicate the score that is risk-adjusted for the measure.
	Is the OCDR measure able to		
AN	be abstracted?	Required	Please attest that the measure element can be abstracted and is feasible.
<u>A0</u>	be abstracted? Please provide any test data on reliability/validity	Optional	feasible. If test data on reliability/validity is not available enter N/A.
<u>ΑΩ</u> <u>ΑΡ</u>	be abstracted? Please provide any test data on reliability-validity Clinical Recommendation Statement	Optional Required	Sabibe. If test data on reliability/validity is not available enter N/A. Provide a concise statement regarding the clinical recommendation for this QCDR measure including the current clinical guideline the measure is derived. encommendation (12: 19 year). The USPSTP recommends screening for MDD in adolescent aged 12 to 18 years. Screening should be implemented with adequate hystemin in place to ensure accurate diagnosis, effective treatment, and agroppid to follow up (B recommendation)" Gui, A. and USPSTP, POIG, p. 340).
	be abstracted? Please provide any test data on reliability/validity Clinical Recommendation	Optional	Easible. If test data on reliability/validity is not available enter N/A. Provide 3 concise statement regarding the clinical recommendation provide 3 concise statement regarding the clinical paideline the measures is deviced. Example: Adolescent Recommendation (12:18 years) The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate pytemin in place to command scurate diagnoid, effective treatment.
<u>ΑΩ</u> <u>ΑΡ</u>	be abstracted? Please provide any test data on reliability/validity Clinical Recommendation Statement Provide the rationale for the	Optional Required	Sealible. If test data on enlability/validity is not available enter N/A. Forvide a concise statement regarding the clinical recommendation for this QCDR measure. Forvide a concise statement regarding the clinical paideline the Exampler. Anlocent Recommendation (12:39 years) The USPSTF recommends screening for MOD in adolescents end 19 The USPSTF recommends screening for MOD in adolescents end 19 The USPSTF recommends concentration (2:39 years) The USPSTF recommendation (2:30 years) The USPSTF recommendation (2:30 years) Provide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide a concise statement regarding the rationale for the QCDR measure. Forvide functioning (Pntt Brody 2014), 2014 U.S. survey data having regards (1:4), 2011 Millio add (1:4), 2015 Millio (4:5) percent having regards Statistics and Quality, 2015). Forvide measure performance gave under be provided. Page provide Relable. ME provided provisional approval with the expectation that relations. Forvide measure performance data and variance rate, If available. ME provide provisional approval with the expectation that relations. Forvide measure performance data and variance rate, If available. Forvide measure performance data and variance rate, If available. Forvide concise statement for the data best on that relations. Forvide provide provisional approval with the expectation that relations. Forvide provide provisio
	be abstracted? Please provide any test data on reliability-validity Clinical Recommendation Statement Provide the rationale for the QCDR measure	Optional Required	Facilite. If test data on reliability/solidity is not available enter N/A. If vest data on reliability/solidity is not available enter N/A. Forvide a concluse statement regarding the clinical autoenter for the CDB masses. Example: Anoisectine Recommendation (12:18 years) This Sorest recommends screening for MED m subsections of 12 by years) This Sorest recommends screening for MED m subsections of 12 by years Provide a concluse statement regarding the rationale for the DD m subsections of 12 by years Provide 10 entry screening for MED m subsections of 12 by years Provide 10 entry screening for MED m subsections of 12 by years Provide 10 entry screening for MED m subsections of 12 by years Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide 1 concluse statement regarding the rationale for the QCDR Provide regard year, with 132 million statilits (3 a precent) saving one MOE Provide measure performance data and volume ration of the Beak periode for Beak periode for Beak periode for Beak periode for Beak periode and beak Provide measure performance data and volume ration and beak periode for Beak periode for Beak periode for Beak periode for Beak period for Beak periods and beak periods for Beak periods and beak periods for Beak periods and period and periods and beak periods and beak periods and beak periods and periods and periods and beak periods and beak periods and beak periods and
	be abstracted? Please provide any test data on reliability-validity Clinical Recommendation Statement Provide the rationale for the QCDR measure	Optional Required	Souble. If test data on enlability/solidity is not available enter N/A. Provide a concise statement regarding the clinical audientiation for this QCDB measure including the current divide and the concentration for this QCDB measure including the current divide and the concentration of the test of the concentration of the current divide and the current of 18 years. Service Haccommendation (12:18 years) The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Service Haccommendation (12:18 years) and appropriate follow-up (B recommendation)' (Sui, A, and USPSTF, 2016, p. 360) Founde 1 provide a social lines associated with measure. Deamagie: Depression is a serious medical lines associated with measure initial lines (11:4 precent) devices of the QCDR measure. Deamagie: Depression is a serious medical lines associated with measure dimension of the test of the test of the test of the measure devices explored (MDE) in the past year with 32 million measure devices explored (MDE) in the past year with 32 million and 43 servers browled experiments and current of the test of the test of the test of the browled experiment of the test of test of test of the test of the test of test
<u><u>AQ</u> <u>AP</u> <u>AQ</u> <u>AQ</u></u>	be abstracted? Please provide any test data on reliability/validity clinical Recommendation Statement Provide the rationale for the QCDR measure Provide the study clistion to happot performance pap for performance data is not	Optional Required	Feasible. If test data on enlability/validity is not available enter N/A. Provide a concise statement regarding the clinical recommendation for this QCD measure interaction of the commendation of the surrent clinical guideline the Example: Adolescent Recommendation (1:2:3) years) The USPIT recommends screening for MCD in adolescents and 12 the particular screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in adolescents and 12 the USPIT recommends screening for MCD in the USPIT resource. Provide a concise statement regarding the rationale for the QCDR measure. The USPIT recommend adding the table screening for MCD in the screening adding the table screening adding the screening adding
<u>60</u> <u>60</u> <u>60</u> <u>86</u> <u>86</u>	be abstracted? Decase provide any test data on reliability-validity Provide the rationale for the QCDR measure Provide the rationale for the QCDR measure Provide the study of table no provide table no	Optional Required Required Required	Festible. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available enter N/A. Provide a conclusibility/validity is not available. Provide a conclusibility/validity is not available. Provide a conclusibility/validity is not available. Provide a conclusibility/validity is not available. Provide a conclusibility/validity is not available. Chi for out clusses increased healt next cont with 15.5 million (6 opercent) adults aged 18 or doer had least one MCE in the 15.7 million (6 opercent) adults aged 18 or doer had least one MCE in the available. Chi provided provident) approval with the cogectation that doer have conclusible or adults and validity or adults. Provide measure performance data and variance rate, rif available.
	be abstracted? be abstracted? lease provide any test data on reliability-validity links a Recommendation Statement frowide the rationale for the QCDR measure provide measure performance data and variance rate, if available provide the absolved bable to performance data is not available ploce hydrate applicable poecially/specialbles performance data applicable poecially/specialbles performance performance data performance provide the applicable poecially/specialbles performance perf	Optional Required Required Required Required Required Required Required Required	Fastible. Frest data on reliability/solidity is not available enter N/A. Froxde a concise statement regarding the clinical recommendation for this QCB measure. Frowde a concise statement regarding the clinical available in the SCDB measure. Frowde a concise statement regarding the clinical publishes to SCDB measure. Frowde a concise statement regarding the clinical publishes to SCDB measure. The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends screening for MOD in adolescents of 12 The USPT recommends of the COD in the SCD in adolescents of 12 The USPT recommends in the screening for MOD in the SCD in adolescents of 12 The USPT recommends adole adolescents of 12 The USPT recommends in the screening for the USPT recommends adolescents of 12 The USPT recommends adolescents of 12 The USPT recommends adolescents of 12 The USPT recommend addle age of 30 or def had at least one MDE in the SCD in the SCD in the screening addle adolescents of 12 The USPT recommend addle age of 30 or def had at least one MDE in the SCD in the SCD in the SCD in the SCD in the SCD in the SCD in the SCD in the SCD in the SCD in the Schemitting the measure within your test of def performance data and variance rate. If available. Comparison address or performance data addle in the Schemitting the measure within your test of def MSE. CAS provided periodicinal addle in the Schemitting period
<u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u>	be abstracted? be abstracted? lease provide any test data on reliability-validity links are commendation Statement rowide the rationale for the QCDR measure provide measure performance data and variance rate, if available Provide the attudy distant to performance data is not available Provide the study distant to performance data is not available Provide the study distant to performance data is not available Provide the study distant to performance data is not available Provide the study distant to performance data is not available Provide the study distant to performance data is not available Provide the study distant to perform the measure published clinical category	Optional Required Required Required Required Required Required Required Required	Sealible. Frest data on reliability/validity is not available enter N/A. Froxde a concise statement regarding the clinical recommendation for this QCDR measure interaction of the commendation of the current clinical guideline the Example: Anolescent Recommendation (1:2:3) years) The USPT recommendations screening for MOD in addiscrents end to the commendation of the current clinical guideline the systems in place to ensure accurate dispussion. How the vertice of the current clinical guideline the systems in place to ensure accurate dispussion. How the vertice resource commendation of the current clinical guideline the systems in place to ensure accurate dispussion. How the vertice resource commends a serious medical lines associated with higher rates of formic clinical encores de hait care culturation, and major depression is a serious medical lines associated with higher rates of formic clinical encores de hait care culturation, and major depression encores and the past year and that 15.7 million (d. p encorent) adults aged 38 or oder haid at least one MEI line with severe imperiment in the past year and that 15.7 million (d. p encorent) adults aged 38 or oder haid at least one MEI line with severe imperiment in the past year and the states of the MEI Statistics and Quality. 2015). Provide measure performance data and variance rate. If available. CMS provided provisional approval with the expectation that the available performance active and the done that are ender of MMS. (CMS provided provisional approval with the ender of MMS, CMS provided provisional approval with the ender of MMS. (CMS provided provisional approval with the ender of MMS, CMS provided provisional approval with the ender of MMS. (CMS provided provisional approval with the ender of MMS, CMS provided provisional approval with the ender of MMS. (CMS provided provisional approval with the ender of M
20 20 20 20 20 20 20 20 20 20 20 20 20 2	be abstracted? becase provide any test data on reliability/validity linka in test data on linka in test data on linka in test data on linka internet rowide the rationale for the QCDR measure performance data and variance rate, if available Provide the study citation to pappot performance gap for performance data is not available Please indicate applicable pecular/specialities Provide the study citation to performance data is not available Please indicate applicable pecular/specialities Provide the study citation to pappot performance data is not available Please indicate applicable pecular/specialities Please indicate applicable pecular/specialities Please pedicate applicable performance complement	Optional Required	Featible. Freed data on endubility/solidity is not available enter N/A. Freed data concluse statement regarding the clinical recommendation for this QCDR measure. Freed data recommendation for this QCDR measure. Freed data concluse statement regarding the clinical recommendation for this QCDR measure. Freed data recommendation for this QCDR measure. The USPST recommends screening for MCD in adoleccents of 12 The USPST recommends concentration (2:18) years) represents in place to ensure accurate disposis, effective relationst. Indigenees the ensure accurate disposis, effective relationst. Indigenees to ensure accurate disposis, effective relationst. Indigenees the ensure accurate data least cone MDE line with severe imperiment in the past year and that 15:20 million (6 a percent) adults aged 38 or dder had at least one MDE line with severe imperiment in the past year and that 15:20 million (6 a percent) adults aged 38 or dder had at least one MDE line with severe imperiment in the past year and that 15:20 million (6 a percent) adults ager 38 or dder had at least one MDE line between a performance actual and variance rate. If available. CMS provided providenal approval with the exact within your eligible clinical and variance rate. If available. Provide measure performance data and variance rate. If available. Provide measure performance data and variance rate. If available. Provide measure performance data dees not sho
<u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u> <u>Δ</u>	be abstracted? Please provide any test data on reliability-validity Please provide any test data on Statement Revolde the rationale for the CCDR measure Provide the study classion to apport performance pay for part performance pay for part performance data is not available Plocate hedicate applicable apportable plocate hedicate applicable apport performance data is not available Plocate hedicate applicable apport performance data is not available Plocate hedicate applicable apportable Plocate hedicate applicable CMS Measure Feedback	Optional Required N/A	Facilitie. Free data on reliability/solidity is not available enter N/A. Frowde a concise statement regarding the clinical recommendation for this QCDR measure the QCDR measure is the commendation of the QCDR measure the QCDR measure is the commendation of QLB years). The USPTF recommends screening for MCD in adolecents of QLB Parameter Alors on enabling with the commendation of QLB years). The USPTF recommends screening for MCD in adolecents of QLB Parameter Alors on enabling with the commendation of QLB years). Provide a concise statement regarding the rationale for the QCDR measure. Provide a concise statement regarding the rationale for the QCDR measure. Provide a concise statement regarding the rationale for the QCDR measure. Provide a concise statement regarding the rationale for the QCDR measure. Provide a concise statement regarding the rationale for the QCDR measure. Provide a concise statement regarding the rationale for the QCDR measure. Provide measure performance data and valence rate. If available. Provide measure performance data and valence rate. If available. Provide measure performance data and valence rate. If available. Provide measure performance data and valence rate. If available. Provide the state of a performance gave vale to a support a pap. the measure will five or the payrowal to be provided. Preasure power performance gave state of a performance gave state does not have performance gavavale tore in the codd performance gavavale to performance gave d

QCDR Organization Name: QCDR Vendor ID (if applicable):

Self-Nomination ticket #: Number of QCDR Measures submitted =

PIMMS Tracking ID (PI	Input Row Completeness
	Incomplete

Incomplete
Incomplete

Error Messages for Required Fields	Measure Submission Status*
Empty Row	

Empty Row Empty Row

Empty Row

Empty Row

Empty Row

Empty Row

Empty Row

Empty Row

Empty Row

*If "NO", see instructions tab

Do you own this measure?* If you do not own or co-own this measure with alf this is a previ	


<u>Measure Title*</u>	Measure Description*

Denominator*	Numerator*	

Denominator Exclusions*	Denominator Exceptions*

Numerator Exclusions*	Data Source Used for the Measure*

If applicable, please enter additional information	



Please indicate what has changed to the existing measure and how the	Can the measure he henchmarked against the n
Please indicate what has changed to the existing measure and now the	<u>Can the measure be benchmarked against the p</u>

If applicable, please Indicate why the prev	NQF ID Number(if appli	Is the QCDR measure a l	<u>High Priority Ty</u>

NQS Domain*	Care Setting*

Which Meaningful Measure Area applies	Meaningful Measure Area Rationale*

Inverse Measure [*]	Proportional Measure*

Continuous Variable NRatio Measure*	If Continuous Variable and/or Rati	Number of perform:

Performance Rate Description(s)	Indicate an Overall Performance Rate

<u>Risk-Adjusted*</u>	If risk-adjusted, indica	Is the QCDR measu

Please provide any test data on reliability/validity	<u>Clinical Recommendation Statement*</u>

New for 2020	New for 2020
Provide the rationale for the Q	Provide measure performance data and vari

Provide the study citation to support performance	Please indicate applicable specialty/specialtie

<u>Preferred measure published clinical category*</u>

QCDR Notes	CMS QCDR Measure Feedback

<u>Vendor QCDR Measure Response</u>	QCDR Measure Reconsideration M

